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Introduction
Proteases perform fundamental processing events in multiple
biological processes in all living organisms (Lopez-Otin and Bond,
2008). To date, more than 560 proteolytic enzymes and homologs
have been cataloged in the human genome (Puente et al., 2003),
which reflects their relevance to physiological and pathological
conditions, including cancer. In fact, proteolytic activity facilitates
spreading of tumor cells and formation of distant metastasis through
degradation of protein components of the extracellular matrix
(Overall and Lopez-Otin, 2002). However, the relationship between
proteolytic enzymes and cancer is much more complex because
these enzymes target a variety of substrates distinct from
extracellular matrix components and influence all stages of tumor
development (Egeblad and Werb, 2002; Freije et al., 2003). Recent
functional studies have also revealed that some proteases exhibit
potent anti-tumor functions (Lopez-Otin and Matrisian, 2007). An
illustrative example is that of MMP-8, a matrix metalloprotease
showing a protective role in cancer through its ability to regulate
the inflammatory response induced by carcinogens (Balbin et al.,
2003). Furthermore, MMP-8 expression by breast tumors correlates
with a lower incidence of lymph node metastasis and confers good
prognosis to breast cancer patients (Gutierrez-Fernandez et al.,
2008). These findings have contributed to extend the known
functions of cancer-associated proteases and emphasize the
importance of targeting specific proteases for cancer treatment
(Lopez-Otin and Overall, 2002; Martin and Matrisian, 2007).
The ADAMTS (a disintegrin and metalloprotease with
thrombospondin domains) family comprises 19 extracellular
metalloproteases closely related to MMPs and ADAMs (Cal et al.,
2002; Apte, 2004; Porter et al., 2005). Gain or loss of function of
different ADAMTSs are involved in serious human diseases such
as osteoarthritis (Bondeson et al., 2008) and thrombotic
thrombocytopenic purpura (Sadler, 2008). In relation to
tumorigenesis, some ADAMTSs are overexpressed in tumors of
different sources (Porter et al., 2005; Rocks et al., 2008), whereas
other family members have been cataloged as tumor-protective
enzymes (Lopez-Otin and Matrisian, 2007). Thus, different reports
point out the angio-inhibitory properties of ADAMTS-1 (Iruela-
Arispe et al., 2003; Kuno et al., 2004; Lee et al., 2006). Moreover,
ADAMTS1 expression has been found epigenetically silenced in
colorectal tumors (Lind et al., 2006). Furthermore, ADAMTS8,
ADAMTS9 and ADAMTS18 gene promoters are also
hypermethylated in several carcinomas (Dunn et al., 2004; Jin et
al., 2007; Lo et al., 2007). ADAMTS-12 is another member of this
family and was originally identified and cloned in our laboratory
(Cal et al., 2001). We have recently described that this enzyme can
modulate the Ras-dependent ERK (extracellular signal-regulated
kinase) signalling pathway in MDCK (Madin-Darby canine kidney)
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suppressor enzymes. We have recently reported that lung
carcinoma cells expressing the ADAMTS-12 metalloprotease
show a remarkable impairment of growth in immunodeficient
mice as compared with parental cells. Here, we show that
ADAMTS12 promoter is hypermethylated in cancer cell lines
and tumor tissues. Interestingly, ADAMTS12 expression in the
stromal cells surrounding epithelial malignant cells is higher
than in the paired normal tissues. Moreover, the expression of
this metalloprotease in colon fibroblasts co-cultured with colon
cancer cell lines is higher than in those cultured alone.
Furthermore, the expression of ADAMTS-12 by these fibroblasts
is linked with an anti-proliferative effect on tumor cells. Based
on these findings, we hypothesize that ADAMTS-12 is a novel
anti-tumor protease that can reduce the proliferative properties
of tumor cells. This function is lost by epigenetic silencing in
tumor cells, but concurrently induced in stromal cells, probably
as part of a response of the normal tissue aimed at controlling
the progression of cancer.
Key words: Metalloprotease, Thrombospondin, Methylation,
Degradome
Summary
The ADAMTS12 metalloprotease gene is
epigenetically silenced in tumor cells and
transcriptionally activated in the stroma during
progression of colon cancer
Angela Moncada-Pazos1, Alvaro J. Obaya2, Mario F. Fraga3, Cristina G. Viloria1, Gabriel Capellá4,
Mireia Gausachs4, Manel Esteller3, Carlos López-Otín1 and Santiago Cal1,*
1Departamento de Bioquímica y Biología Molecular and 2Biología Funcional, Area de Fisiología, Facultad de Medicina, Instituto Universitario de
Oncología, Universidad de Oviedo, 33006 Oviedo, Spain
3Cancer Epigenetic Laboratory, Spanish National Cancer Centre (CNIO), 28029 Madrid, Spain
4Laboratori de Recerca Translacional, IDIBELL, Institut Català d’Oncologia, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
*Author for correspondence (santical@uniovi.es)
Accepted 5 June 2009
Journal of Cell Science 122, 2906-2913 Published by The Company of Biologists 2009
doi:10.1242/jcs.050468
2907Anti-tumor properties of ADAMTS-12
cells, and that subcutaneous tumors induced by A549 lung
carcinoma cells expressing ADAMTS12 display a considerable
growth deficiency as compared with those induced by parental cells
(Llamazares et al., 2007). To further examine the relevance of
ADAMTS-12 as a putative tumor-suppressor enzyme, we have
analyzed the mechanisms controlling its expression in cancer cells
and tissues with the finding that ADAMTS12 is epigenetically
silenced in tumor cell lines from multiple sources, whereas it is
transcriptionally activated in stroma cells. Our data strongly suggest
that ADAMTS-12 is part of a protective host response against tumor
progression derived from the intimate crosstalk between tumor cells
and the surrounding stroma.
Results
ADAMTS12 gene promoter is hypermethylated in colorectal
carcinomas and colon cancer cell lines
Analysis of 2.0 kb upstream and 0.5 kb downstream of the first
ATG codon allowed the identification of a CpG island in this region,
suggesting the potential influence of CpG methylation in the
transcription of the ADAMTS12 gene. Methylation-specific PCR
(MSP) amplification of a 138 bp promoter within the CpG island
(Fig. 1A) was performed on a set of paired normal and tumor colon
samples. As can be seen in Fig. 1B, the methylation level of
ADAMTS12 promoter was higher in 12 out of 19 (63.2%) biopsies
of primary colorectal tumors than in the corresponding normal
tissue. Similarly, MSP amplification using genomic DNA from the
microsatellite-stable (MSS) SW620, SW480, COLO 205 and HT29
colon carcinoma cell lines, and the microsatellite-unstable (MSI)
DLD-1, HCT 15, HCT-116, LoVo and RKO cell lines showed that
ADAMTS12 promoter is hypermethylated in all of them, with the
exception of LoVo cells (Fig. 1B; Table 1).
We next performed high-resolution bisulfite genome sequencing
of 26 CpG sites within the CpG island identified (Fig. 1A). Eleven
colon carcinoma samples were selected for this assay, attending to
the different intensities of PCR products in previous MSP
amplifications. Seven of these samples were more methylated in
the tumor than in their paired normal tissues (Fig. 1C; Table 1).
Among them, tumor samples 426, 467 and 557 were highly
methylated in most of the 26 CpG sites examined (70-90%). By
contrast, their paired normal tissues were much less methylated (20-
40%). Four additional tumor samples, 340, 401, 478 and 566,
showed percentages of methylation ranging between 20 and 60%,
but their paired normal tissues were scarcely methylated (below
10%). Samples 404 and 496 showed similar levels of methylation
in both tumor and normal tissues, whereas samples 397 and 555
were more methylated in normal tissues. Parallel analysis carried
out in colon carcinoma cell lines revealed the high frequency of
methylation at these CpG sites, independently of the microsatellite
instability status. Thus, percentages of 80-90% were determined
for SW620, SW480 and COLO 205 (MSS cell lines), and for
Fig. 1. Epigenetic silencing of ADAMTS12 in
colon cancer. (A) Schematic representation of
the ADAMTS12 CpG island. An interval of
2.0 kb upstream and 0.5 kb downstream from
the first ATG codon of ADAMTS12 was
analyzed for CpG islands. Thin black arrow
indicates the transcription start site; white
arrows indicate MSP primers and thick black
arrow BSP primers. (B) Methylation status of
ADAMTS12 in primary colon carcinomas and
colon cancer cell lines. PCR-methylation
analysis was carried out in paired normal (N)
and tumor tissues (T), using the specific
primers for either methylated (M) or
modified unmethylated DNA (U). Genomic
DNA from human lymphocytes was used as a
control for unmethylated DNA (NL), and the
CpGenome Universal Methylated DNA as
control for methylated DNA (IVD).
(C) Methylation density of ADAMTS12 in
colon cancer. Primary tumor samples and
colon cancer cells were subjected to bisulfite
treatment, and PCR amplification was
performed using BSP primers. Relative
positions of each CpG analyzed and the
distance in bp are indicated in the control for
unmethylated DNA (NL). Methylation
percentages for the rest of the tumor samples
examined are indicated in Table 1. Colors
shows the methylation density of each CpG:
yellow, methylated; blue, not methylated;
grey, not present. (D) Activation of
ADAMTS12 expression in colon cancer cell
lines. Indicated cell lines were treated with
5-aza-2-deoxycitidine (Aza), or Aza + TSA.
ADAMTS12 expression was assayed by RT-
PCR. N.T., no treatment. GAPDH mRNA
was amplified as an internal control.
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DLD-1, HCT-116 and RKO (MSI cell lines) (Fig. 1C; Table 1).
The percentage of methylation for HCT 15 cells was 66.8% and,
consistent with the above MSP analysis, ADAMTS12 gene promoter
was found barely methylated in LoVo cells (Table 1).
The above results strongly suggested that promoter methylation
could silence ADAMTS12 gene expression. To examine this
possibility, we selected the MSS cell lines SW480 and SW620, and
the MSI cell lines DLD-1 and HCT-116 to perform RT-PCR
amplification. As illustrated in Fig. 1D, none of these cell lines
expressed ADAMTS12. It is also remarkable that none of the
additional cells employed in the methylation analysis showed
appreciable levels of ADAMTS12 expression (not shown). Then,
we investigated whether ADAMTS12 expression could be restored
by treatment with the demethylating agent 5-aza-2-deoxycitydine
(Aza). This treatment was carried out with or without the histone
deacetylase inhibitor trichostatin A (TSA), which has also been used
to examine the methylation status of ADAMTS18 (Jin et al., 2007).
As shown in Fig. 1D, ADAMTS12 expression could be reinstated
following drug treatment. Moreover, this activation was observed
in DLD-1 and HCT-116 cells even in the absence of TSA. Taken
together, these results provide evidence for the epigenetic silencing
of ADAMTS12 expression in colon carcinomas.
Expression of ADAMTS12 in colon carcinomas
Next, we used RT-PCR to study expression levels of ADAMTS12
in the set of colon cancer samples previously used to examine their
methylation status (Table 1). Interestingly, and in contrast to what
could be expected from the previous results, ADAMTS12 expression
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levels were higher in tumor samples than in normal tissues (Fig.
2). These tumor biopsies contained at least 50% tumor cell content
but no attempt at tumor-cell enrichment was made. A similar result
was obtained when PCR amplification was performed using a set
of five commercially available paired normal and tumor cDNA
samples from colon carcinomas (Fig. 2). As a positive control for
this analysis, we performed PCR amplification of SFRP1, a gene
known to be silenced by methylation in colon cancer (Aguilera et
al., 2006).
Induction of ADAMTS12 expression in stromal cells
A possible explanation for above unexpected result is that
ADAMTS12 is produced by stromal cells in the immediate vicinity
of neoplastic epithelial cells and not by the tumor cells themselves.
To evaluate this possibility, we performed an immunofluorescence
study using 20 colon carcinoma tissue sections. As can be seen in
Fig. 3A, double immunofluorescent staining for ADAMTS-12 and
alpha smooth muscle actin (α-SMA) showed a close approximation
of ADAMTS-12 immunoreactivity to α-SMA-positive cells. By
contrast, there was no staining in epithelial cells. Moreover, detailed
examination of 55 tissue areas revealed that 60% of areas of well-
differentiated and moderately differentiated carcinomas showed a
strong immunoreactivity for ADAMTS-12 (Table 2), and only two
areas of the moderately differentiated carcinomas lacked staining
for ADAMTS-12. However, only 36% of areas of advanced poorly
differentiated carcinomas showed strong immunostaining for the
enzyme, whereas 48% of these areas lacked staining, which is
consistent with the relative low proportion of myofibroblasts in these
Table 1. Hypermethylation of the ADAMTS12 promoter
Patient sample Microsatellite Mean CpG site methylation (%) Methylation
Cell lines number instability Normal Tumor status
340 MSS 9.80 25.80 M
362 ND ND ND M
369 MSS ND ND M
372 MSI ND ND M
397 ND 49.33 13.75 U
401 MSI 0.64 20.33 M
404 MSS 17.39 22.05 U/M
426 MSS 21.42 82.25 M
467 MSS 9.23 84.07 M
468 MSS ND ND U/M
478 MSS 4.33 25.96 M
495 MSS ND ND M
496 MSS 11.11 19.61 U/M
529 ND ND ND U/M
551 MSS ND ND M
555 MSS 35.34 20.07 U
557 MSS 31.61 70.76 M
566 MSS 7.40 59.24 M
588 ND ND ND U
DLD-1 MSI 85.74 M
COLO 205 MSS 82.21 M
HCT-116 MSI 86.51 M
HCT 15 MSI 66.79 M
HT29 MSS ND M
LoVo MSI 9.58 U
RKO MSI 80.76 M
SW480 MSS 82.14 M
SW620 MSS 84.10 M
MSP amplification using genomic DNA from the microsatellite-stable COLO 205, HT29, SW620 and SW480 colon carcinoma cell lines, and the
microsatellite-unstable DLD-1, HCT 15, HCT-116, LoVo and RKO cell lines was used to measure methylation of the ADAMTS12 promoter. Samples were also
analyzed from paired normal and primary colorectal tumor tissue from 19 patients.
U, unmethylated; M, methylated; MSS, microsatellite-stable; MSI, microsatellite-unstable; ND, not determined.
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undifferentiated tumours. Expression in normal mucosa or
adenomatous polyps was not or hardly detectable. These data
indicate that the expression of ADAMTS12 is due to fibroblastic-
like cells present in the stroma surrounding malignant cells.
Moreover, these results point to a correlation between the expression
of this metalloprotease and the histopathologic grade of tumors.
To examine whether colon fibroblasts could express the
metalloprotease gene, we carried out co-cultures of CCD-18Co
colon fibroblasts with colon cancer cells, and used quantitative RT-
PCR to compare the differences in ADAMTS12 expression levels
with those detected in fibroblasts cultured alone. To discard any
possible presence of tumor cells mixed with the fibroblasts following
co-culture, absence of RT-PCR amplification of the carcinoma
marker EpCAM (Trzpis et al., 2007) was also assayed (not shown).
As illustrated in Fig. 3B, fibroblasts showed about twofold higher
ADAMTS12 expression when co-cultured with SW620 and DLD-
1 cells, and fivefold higher levels in the case of co-culture with
SW480 colon cancer cells. Additionally, we found that TGF-α (4.5-
fold), TGF-β1 (3.3-fold), and IL-6 (twofold) also raised ADAMTS12
expression in these fibroblasts. By contrast, treatment with IL-10
did not modify the expression levels of this metalloproteinase. Next,
we examined whether the enhanced expression of ADAMTS12
observed in fibroblasts co-cultured with tumor cells could be
promoted by any of the analyzed cytokines. To this end, we
employed different blocking antibodies and found that a
considerable reduction of the metalloprotease expression was
observed when blocking antibodies against TGF-β1 were added to
the co-cultures, but not in the presence of blocking antibodies against
TGF-α (Fig. 3C). ADAMTS12 expression was not detected in tumor
cells in the course of these experiments (not shown).
Then, we asked whether this induced expression of ADAMTS12
in colon fibroblasts could be associated with any functional effect.
To evaluate this possibility, we selected SW620 (MSS) and DLD-
1 (MSI) cells because of the similar enhancement of ADAMTS12
expression caused in CCD-18Co fibroblasts (Fig. 3B). Growth rates
for the colon cancer cells were calculated during the exponential
growth phases in co-culture with colon fibroblasts. Cancer cells
cultured alone on the inserts were used as control. Results indicated
that both cell lines had growth defects. The doubling time for DLD-
1 cells in co-culture with fibroblasts was 16.9 hours, whereas it was
13.9 hours when the cell line was cultured alone. This difference
was even more significant in the case of SW620 cells: the doubling
times were 31.5 hours in co-culture and 25.7 hours in the absence
of fibroblasts. We also determined the percentage of apoptotic cells
in the assayed conditions after 96 hours of incubation (Fig. 3D).
Analysis of DLD-1 revealed that the apoptotic cell population was
34% in co-culture with colon fibroblasts, and 25.5% when the tumor
cell line was cultured alone. Potency of apoptosis induction by the
fibroblasts was higher in case of SW620 cells: 36.5% of tumor cells
were apoptotic in co-culture, but only 12.5% in the absence of
fibroblasts. This study indicates the occurrence of a decrease in
tumor cell proliferation concomitant with enhanced ADAMTS12
expression.
Taken together, these findings indicate that ADAMTS-12 is
mainly secreted by the stromal cells surrounding cancer cells in
colon carcinomas. This stromal expression of ADAMTS12 might
suggest the occurrence of a protective response, which tries to
compensate for the epigenetic silencing of this gene in malignant
cells.
ADAMTS12 expression is epigenetically silenced in tumors of
different origin
The above results obtained in colon cancer tissues and cell lines
prompted us to extend our study on ADAMTS12 expression to
tumors of different origins through methylation analysis of
additional tissues and cell lines. We employed the Illumina
GoldenGate methylation platform to study the DNA methylation
status of two CpG positions within the ADAMTS12 CpG island in
a panel of normal tissues and cancer cell lines. As shown in Fig.
4, ADAMTS12 was found to be highly hypermethylated in most of
the analyzed tumor cell lines (21 out of 29 for probe P250, and 26
out of 29 for probe E52). By contrast, methylation was scarcely
detected or not detected in the normal tissues examined. Overall,
these results provide additional evidence to indicate that ADAMTS12
is an epigenetically silenced gene in tumor cells of diverse origin
and to support its potential role as a tumor suppressor gene.
Interestingly, this study also showed that the promoter region of
ADAMTS12 is not methylated in LoVo cells (probe P250), which
perfectly agrees with the results obtained from MSP and bisulfite-
sequencing PCR (BSP) analysis (Fig. 1). However, this gene is
highly methylated in these cell lines in a region contained within
its first exon (E52). Thus, it could not be ruled out that methylation
in positions other than those previously examined by BSP in this
work could control the silencing of ADAMTS12 expression.
Discussion
In this work, we have found that the ADAMTS12 gene is subjected
to a generalized methylation process in colorectal tumors and in a
variety of tumor cells from different origins, a mechanism of
growing relevance in the inactivation of tumor-suppressor genes
(Esteller, 2007). We have also proven that ADAMTS12 expression
can be induced in CCD-18Co fibroblasts and is associated with a
decrease in proliferation and an increase in apoptosis of the adjacent
tumor epithelial cells. Finally, histopathologic analysis has revealed
that ADAMTS-12 is detected in stromal cells from well-
differentiated and moderately differentiated tumors rather than in
Fig. 2. ADAMTS12 expression in human colon carcinomas. Top and middle
panels: total RNA from the indicated colon carcinoma samples was isolated
and ADAMTS12 expression was assayed by RT-PCR (N, normal; T, tumor).
The remaining colon carcinoma samples employed in this work were
discarded for this analysis because of RNA quality. Bottom panel:
amplification of ADAMTS12 from a set of five (A-E) commercially available
paired normal and tumor first-strand cDNA samples from colon carcinomas.
Amplification of SFRP1 was used as positive control. In all experiments, RT-
PCR of GAPDH mRNA was used as an internal control.
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those from advanced poorly differentiated carcinomas. Taken
together, these results reinforce the proposal that ADAMTS-12 is
a novel protease that can be included in the growing category of
proteolytic enzymes with tumor-defying properties (Lopez-Otin and
Matrisian, 2007).
ADAMTS-12 belongs to a family of metalloproteases that has
been commonly associated with cancer (Rocks et al., 2008).
Nevertheless, the functional relevance of these enzymes in tumor
progression is still unclear and in some cases contradictory. On
the one hand, ADAMTS-4 and ADAMTS-5 contribute to
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invasiveness of glioblastoma cells through their ability to cleave
brevican (Held-Feindt et al., 2006), therefore acting as pro-tumor
proteases. On the other hand, and similar to our findings on
ADAMTS-12, ADAMTS-8, ADAMTS-9 and ADAMTS-18 have
been proposed to act as anti-tumor enzymes because the genes
encoding these proteases have been found hypermethylated in
tumors of different origins (Dunn et al., 2004; Jin et al., 2007; Lo
et al., 2007). Interestingly, ADAMTS-1 plays a dual role in cancer
because it exhibits both pro- and anti-tumor properties (Vazquez
et al., 1999; Masui et al., 2001; Iruela-Arispe et al., 2003; Kuno
Fig. 3. Induction of ADAMTS12 expression in stromal cells.
(A) Immunofluorescence detection of ADAMTS-12 in colon
carcinoma tissue sections. Detection of activated fibroblasts
was performed using an anti-SM α-actin monoclonal
antibody. ADAMTS-12 was detected using the H-142
antibody from Santa Cruz Biotechnology. Representative
tissue sections corresponding to normal mucosa (NM),
adenomatous polyp (AP), and well-differentiated (WD),
moderately differentiated (MD) and poorly differentiated
(PD) carcinomas are shown. Insets show higher
magnifications of sections marked with a square. Scale bars:
50 μM. (B) Induction of ADAMTS12 expression was assayed
by co-culture of CCD-18Co fibroblasts with the indicated
colon cancer cells, or through treatment with the indicated
cytokines. After 36 hours, ADAMTS12 expression was
determined by quantitative PCR. Actin expression was
simultaneously analyzed as internal control. (C) Anti-TGF-β1
blocking antibodies reduce ADAMTS12 expression by
fibroblasts co-cultured with tumor cells. A remarkable
reduction of ADAMTS12 expression was detected when anti-
TGF-β1 blocking antibodies were added to the co-cultures,
whereas the presence of these antibodies did not show any
direct effect on the metalloprotease expression. (D), Induction
of apoptosis in colon cancer cells. DLD-1 and SW620 cells
were co-cultured with CCD-18Co fibroblasts or cultured
alone, and the percentage of apoptotic tumor cells was
determined after 96 hours. (B,C,D) Data are means ± s.e.m.
Statistical significance was determined using a Student’s t-test
(***P<0.001, **P<0.01, *P<0.05).
Table 2. ADAMTS12 expression and histopathologic grade in colorectal carcinoma
Number of areas Degree of staining
Sample type examined – +/– +
Adenomatous polyp 5 3 (60%) 2 (40%) 0 (0%)
Adenocarcinoma Well-differentiated 5 0 (0%) 2 (40%) 3 (60%)
Moderately differentiated 20 2 (10%) 6 (30%) 12 (60%)
Poorly differentiated 25 12 (48%) 4 (16%) 9 (36%)
All types 55 17 (31%) 14 (25.4%) 24 (43.6%)
Twenty samples of adenomatous polyps and different grades of carcinomas were immunostained for ADAMTS-12, and 55 tissue areas examined in detail. The
number and percentage of areas stained were calculated for each different group. – indicates no staining, +/– moderate staining, + intense staining. Staining
resulted negative in the case of normal mucosa.
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et al., 2004; Lee et al., 2006; Lind et al., 2006). An explanation
for these controversial effects might derive from the fact that this
metalloprotease undergoes proteolytic processing events and the
generated forms display tumor-protective or tumor-promoting
properties depending on the cleavage site (Liu et al., 2006). It has
been reported that the ADAMTS-1 thrombospondin domains are
responsible for this protective role through their ability to sequester
growth factors like vascular endothelial growth factor (Luque et
al., 2003; Kuno et al., 2004). The capacity of thrombospondin
domains to inhibit the function of growth factors, together with
their pro-apoptotic actions (Mirochnik et al., 2008), could also
help to explain the effects herein described in colon cancer cells
in the presence of ADAMTS-12.
Histopathologic analysis has revealed that ADAMTS-12 is
detected in the stroma of well-differentiated tumors rather than in
advanced carcinomas. It is noteworthy that immunofluorescent
double-staining analysis for ADAMTS-12 and α-SMA resembles
that shown for periostin, which is expressed by stromal cells in
colon carcinoma (Kikuchi et al., 2008). Periostin is a secreted
extracellular matrix protein found in close proximity to the cells
responsible for its expression, theα-SMA-positive cancer-associated
fibroblasts. The roles of periostin in cancer appear to be quite
diverse, but studies with periostin-deficient mice have shown that
this protein negatively regulates tumor growth by promoting capsule
formation. This suggests that, similar to our proposal for ADAMTS-
12, periostin can also function as an anti-tumor protein (Shimazaki
and Kudo, 2008).
In this work, we also found that ADAMTS12 expression is
enhanced in colon fibroblasts co-cultured with colon cancer, which
is linked to an anti-tumor effect on cancer cells. On this basis, we
speculate that the expression of this metalloprotease could form
part of a stromal response promoted by cancer-associated fibroblasts
to control the pro-angiogenic properties induced by different soluble
growth factors. These fibroblasts, also termed myofibroblasts, are
the predominant cell type in the stroma of most carcinomas
(Ronnov-Jessen et al., 1996) and constitute a heterogeneous
population of cells that cannot always be identified as α-SMA-
positive (Sugimoto et al., 2006). These cells are phenotypically
different from fibroblasts present in normal tissue, but similar to
those found in wounds during the healing process (Gabbiani, 2003).
Myofibroblasts are intricately interwoven with the epithelial tumor
cells (Micke and Ostman, 2004) and, therefore, different pro-tumor
or anti-tumor responses can be elicited by the stroma as a
consequence of its interaction with the malignant cells (Mueller
and Fusenig, 2004).
Among the cytokines assayed in this study, TGF-α and TGF-β1
induced the highest levels of ADAMTS12 expression when the
human colon fibroblasts were cultured alone. However, the use of
blocking antibodies in co-cultured assays suggests that TGF-β1
could be one of the factors responsible for expression of the
metalloprotease as a consequence of the crosstalk between tumor
and stromal cells. This finding perfectly agrees with previous studies
showing that TGF-β1 is one of the main inducers of ADAMTS gene
expression, including that of ADAMTS12, in different conditions
(Cal et al., 2001; Wang et al., 2003). Moreover, Porter et al. have
also reported that ADAMTS12 mRNA levels are higher in stromal
fibroblasts than in epithelial tumor cells from breast cancer (Porter
et al., 2004), a type of tumor that commonly expresses high levels
of TGF-β1 (Chang et al., 2007). Altogether, these findings indicate
that, following its induction in stromal fibroblasts through the action
of factors such as TGF-β1, ADAMTS-12 might act as a tumor-
protective protease in colon cancer and also in tumors of different
origin such as breast cancer. Finally, the fact that other members
of this metalloprotease family have also been found in stromal cells
but not in the corresponding cancer cells (Cross et al., 2005), leads
us to propose that stromal expression of different ADAMTSs could
be a common feature in tumor development or progression.
In summary, we provide new data indicating a dual regulation
of ADAMTS-12 expression in colon carcinoma: epigenetic
inactivation in epithelial malignant cells and induction in
myofibroblasts, suggesting that this metalloprotease could form part
of a protective stromal response aimed at limiting tumor progression.
Our data also suggest that ADAMTS-12 might have potential
clinical applications because this enzyme could be a prognosis
marker not only in colon cancer but also in other tumors in which
ADAMTS-12 is detected (Cal et al., 2002). However, further studies
will be necessary to determine the precise role of ADAMTS12
expression during progression of colon cancer. Likewise, analysis
of susceptibility to colon cancer in Adamts12-null mice, currently
ongoing in our laboratory, will help to clarify the precise role of
this enzyme in the context of the growing number of tumor-defying
proteases that are known to be produced by human cells.
Materials and Methods
DNA samples
Genomic DNAs from paired normal and tumor colon samples were obtained from
19 patients undergoing surgery at the Catalan Institute of Oncology (Barcelona, Spain).
Genomic DNA from human lymphocytes was used as a control for unmethylated
DNA, and the CpGenome Universal Methylated DNA (Chemicon), for methylated
Fig. 4. DNA methylation analysis of the ADAMTS12 promoter in a panel of
normal tissues and cancer cell lines using bead arrays. Methylation was
assessed at two CpG sites within the ADAMTS12 CpG island using Illumina
Goldengate Methylation Arrays. The first CpG site was located 250 bp
upstream of the transcriptional start site (P250) and the second CpG site was
located 52 bp downstream the transcriptional start point (E52). The amount of
bisulfite-modified target DNA that hybridizes to each spot of the Illumina chip
was quantified and standardized over a scale from 0.0 to 1.0 (effectively 0%
and 100% likelihood of gene promoter hypermethylation, respectively).
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DNA. A set of five paired normal and tumor colon cDNA samples to evaluate
ADAMTS12 expression was purchased from Clontech.
Cell culture
Colon cancer cell lines and CCD-18Co fibroblasts were from the American Type
Culture Collection. Cells were routinely maintained in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS), 100
U/ml penicillin and 50 μg/ml streptomycin.
CpG island identification and DNA methylation analysis
An interval of 2.0 kb upstream and 0.5 kb downstream from the first ADAMTS12
ATG codon was analyzed for CpG island identification using the Methyl Primer
Express Software v1.0, (https://produtcs.appliedbiosystems.com). This program was
also used to design MSP primers. Primers for the unmethylated reaction were
5-GAGTTTGGGAGGAAGATGTATT-3 and 5-CTAACAATATCC ACTTT CA -
AC A AAA-3, and for the methylated reaction 5-GAGTTCGGGAGG AAGAT -
GTATC-3 and 5-ACAATATCCGCTTTCGACG-3. To analyze methylation density
of genomic DNA, two BSP primers, 5-TGGTTTGGGGGTTTTTTATT-3 and 5-
AACTAAACACCTTTTTCCCCTC-3, were designed using the indicated program.
Bisulfite-modified genomic DNA from paired normal and tumor tissues and cell lines
was used as template.
RT-PCR amplification
Total RNA from tissue samples and cell lines was isolated by guanidium thiocyanate-
phenol-chloroform extraction and reverse-transcription reactions were carried out with
300 ng of RNA, using the Thermoscript RT-PCR system with Platinum Taq
polymerase (Invitrogen). The ADAMTS12-specific primers used were 5-CAG -
AAAGGACATCTTGCTGG-3 and 5-TCCTGGCAGAAGGTGCATTC-3. PCR
amplifications were performed under the following conditions: one cycle at 95°C for
1 minute, and 35 cycles at 95°C for 15 seconds, 55°C for 15 seconds and 72°C for
30 seconds. GAPDH was amplified as an internal control.
Treatment of colon cancer cell lines with demethylating agents
Colon cancer cells were seeded in 10 mm dishes and incubated in culture media with
10 μM Aza for 3 days. For the combined treatment, cells were treated for 3 days
with Aza and subsequently with 10 ng/ml TSA for 24 hours. ADAMTS12 expression
before and after treatment was determined by RT-PCR.
Co-culture assays and cytokine treatment
Induction of ADAMTS12 expression in colon fibroblasts was examined through their
co-culture with colon cancer cell lines or by cytokine treatment. For co-cultures,
subconfluent CCD-18Co fibroblasts in six-well dishes were cultured with cell-culture
inserts (8.0 μm pore size; BD Biosciences) overlaid with the indicated colon cancer
cell lines and incubated for 36 hours in DMEM medium containing 0.25% FBS.
Cytokines were added to CCD-18Co fibroblasts cultured in six-well dishes at 2 ng/ml
final concentration (except TGF-α, which was used at 25 ng/ml). Then, 9 μl of a 1:5
dilution of cDNA was employed in quantitative PCR using TaqMan probe
HS00917112_m1, TaqMan Master Mix and AbiPrism 7900HT (Applied Biosystems).
When indicated, anti-TGF-α or anti-TGF-β1 blocking antibodies (Calbiochem) were
added to the co-cultures at 1.5 μg/μl. Actin expression was analyzed as an internal
control. Statistical significance was determined using a Student’s t-test. For
determination of cell growth, overlaid colon cancer cell lines (SW620 and DLD-1)
were trypsinized and counted directly in a hemocytometer. After plotting total cell
number against time, data were adjusted to exponential curves from where doubling-
time and regression values were calculated. For apoptosis analysis, 5105 cells were
evaluated using the Anexin V-FITC/IP kit from Sigma-Aldrich. Each cell population
was identified in a Cytomics FC500 (Beckman-Coulter).
Tissue immunofluorescence analysis
Paraffin-embedded colon tissues from 20 different tumors were cut into 5-micron
sections and mounted onto glass slides. The sections were deparaffinized in xylene
followed by ethanol hydration. Samples were permeabilized for 30 minutes with 0.1%
Triton X-100 and incubated for 15 minutes in PBS with 0.1 M glycine. Nonspecific
labeling was blocked with 5% BSA in PBS for 30 minutes. Sections were incubated
overnight at 4°C with an anti alpha smooth muscle primary antibody (α-SMA, dilution
1:50; DakoCytomation) to detect activated fibroblasts. After incubation, sections were
washed with PBS and PBS-Tween 20 (0.5% v/v), and then incubated with Alexa
Fluor 546-conjugated goat anti-mouse antibody (dilution 1:500; Invitrogen) for 45
minutes at room temperature. After washing with PBS and PBS-Tween, sections were
then incubated with a second primary antibody against ADAMTS-12 (H-142, dilution
1:25; Santa Cruz Biotechnology) overnight at 4°C and washed. H-142 is a polyclonal
antibody raised against amino acids 1441-1582 of the human ADAMTS-12. Alexa
Fluor 488-conjugated goat anti-rabbit antibody (dilution 1:200; Invitrogen) was added
and incubated for 45 minutes at room temperature. The corresponding negative
controls were set by omitting the anti-ADAMTS-12 antibody. We then washed the
slides and stained nuclei with 4-6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich)
at 1 μg/ml in Vectashield mounting medium (Vector Laboratories). Images were
obtained using a confocal microscope, Leica TCS-SP2-AOBS.
Analysis of DNA methylation status using bead arrays
Methylation analysis of ADAMTS12 promoter in a panel of normal tissues and cancer
cell lines was assessed using Illumina Goldengate Methylation Arrays (Bibikova et
al., 2006). The two CpG sites analyzed were located 250 bp upstream and 52 bp
downstream of the ADAMTS12 transcriptional start point (E52). Thge amount of
bisulfite-modified target DNA that hybridizes to each spot of the Illumina chip was
quantified and standardized over a scale from 0.0 (0% likehood of gene promoter
methylation) to 1.0 (100% likelihood of gene promoter hypermethylation).
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